Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo)

Nephrology Dialysis Transplantation

Volumn 18, Issue 2, 2003, Pages 362-369

  Locatelli, Francesco ^a   Canaud, Bernard ^b   Giacardy, Francis ^c   Martin Malo, Alejandro ^d   Baker, Nigel ^e   Wilson, Janet ^e  

^a A MANZONI HOSPITAL   (Italy)

^b LAPEYRONIE HOSPITAL   (France)

^c Centre Hospitalier Intercommunal   (France)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e AMGEN LTD   (United Kingdom)

Author keywords

Darbepoetin alfa; Dose requirements; Intravenous; Renal anaemia; Subcutaneous; Unit dosing

Indexed keywords

FERRITIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA MULTIFORME; FEMALE; FERRITIN BLOOD LEVEL; FREQUENCY ANALYSIS; HEADACHE; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPOTENSION; INJECTION PAIN; KIDNEY DISEASE; LUNG EDEMA; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; PRURITUS; URTICARIA;

AGED; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETREATMENT; SAFETY;

EID: 0037317083     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/18.2.362     Document Type: Article

References (16)

1. Aljama P, Bommer J, Canaud B et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001; 16 [Suppl 3]: 22-28
2. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395
3. Bochicciho T, Correa-Rotter R, Trinidad RP et al. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin when administered at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) in dialysis patients in Mexico. J Am Soc Nephrol 2001; 352A: A1812
4. Coyne D, Ling BN, Toto R, McDermott-Vitak AD, Trotman ML, Jackson L. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO). J Am Soc Nephrol 2000; 11: A1380
5. Graf H, Lacombe J-L, Braun J, Gomes da Costa AA, the European/Australian NESP 980140/194 Study Group. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hgb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in ESRD patients. J Am Soc Nephrol 2000; 11: A1317
6. Nissenson AR, Swan SK, Lindberg JS et al. Randomized controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 110-118
7. Vanrenterghem Y, Jadoul M, Foret M, Walker R and the European/Australian NESP 2000-0144 Study Group. Novel erythropoiesis stimulating protein (NESP) administered once every 3 weeks by the intravenous or subcutaneous route maintains hemoglobin (Hb) in dialysis patients. J Am Soc Nephrol 2001; 365A: A1878
8. Vanrenterghem Y, Barany P, Mann JFE et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62: 2167-2175
9. Braun J on behalf of the 20000144 Study Group. Darbepoetin alfa administered once every 4 weeks maintains Hb levels in patients with chronic kidney disease (CKD) receiving dialysis. Nephrol Dial Transplant 2002; 17 [Suppl 12]: 136 (Abstract M317)
10. Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-747
11. Suranyi M, Walker R, Jackson L, Feaster J, McDermott-Vitak A. Novel erythropoiesis stimulating protein (NESP) administered once every other week corrects anemia in patients with early chronic kidney disease. J Am Soc Nephrol 2001; 363A: A1873
12. Canaud B. Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients. Nephrol Dial Transplant 2002; 17 [Suppl 12]: 137 (Abstract M319)
13. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 [Suppl 5]: 1-50
14. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30 [Suppl 3]: S192-S240
15. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Haemodialysis Patients. N Engl J Med 1998; 339: 578-583
16. Besarab A, Flaharty KK, Erslev AJ et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992; 2: 1405-1416